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Acceptability of medicines for children is a challenge, yet critical to ensure adherence to treatment. 26 
There is very little literature on formulation factors that influence acceptability of medicines, 27 
particularly in the domiciliary environment. This pragmatic study was conducted at University 28 
Hospital Coventry and Warwickshire (UHCW) with the aim of identifying the prevalence and nature 29 
of oral formulation-related barriers to medicines administration in children suffering from long-term 30 
conditions.  31 
This study used semi-structured face-to-face interviews with 221 parents/carers of children (0-18 32 
years) and 57 young people (12-18years). 33 
Results showed significant medicines refusal and manipulation in the domiciliary environment. 34 
Nearly one-third (71/232) of respondents reported medicines refusal. This was associated 35 
significantly with the age of child (p=0.016), socioeconomic status (IMD 2010 score)(p=0.002), taste 36 
(p<0.001), texture (p=0.017), and volume (of liquid/powder) or quantity (of solid dosage form) 37 
(p<0.001). 29%(74/252) of respondents reported manipulating medicines. P-values are based on 38 
multivariable statistical analysis models. 39 
This study has indicated that formulations prescribed to children with chronic conditions are not 40 
meeting the needs of a significant number of patients based on self-report. Age-appropriate 41 
medicines are required to provide suitable dose units with an acceptable taste for children. This 42 
study should aid pharmaceutical companies to prioritise paediatric formulation work. 43 
  44 
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1 Introduction 45 
Approximately 200 million prescriptions are issued annually for children and young people in the UK 46 
(Costello et al., 2004). Previous studies have investigated medicines adherence in children, however 47 
these have not explored potential barriers to adherence in the domiciliary setting. In this paper, 48 
barriers are defined as obstacles that could result in non-adherence of medicines (e.g. forgetting, 49 
refuse, hard to swallow, etc.). 50 
There is a paucity of studies investigating   barriers to medicines administration arising from oral 51 
formulations (particularly those related to organoleptic and physical properties) in children with 52 
chronic conditions. Those studies reported previously are limited to specific disease groups, e.g. 53 
antiretroviral medicines in Human Immunodeficiency Virus (HIV) (Boni et al., 2000; Gibb et al., 2003; 54 
Goode et al., 2003; Marhefka et al., 2004; Pontali et al., 2001; Wrubel et al., 2005). Further studies 55 
compare the acceptance and flavour preferences of a spectrum of drugs from one class (e.g. 56 
antibiotics) using a “one-off” taste test method, commonly with the aid of a visual analogue scale 57 
(VAS) most often in healthy children or adults (Bagger-Sjöbäck and Bondesson, 1989; Chan et al., 58 
1997; Cohen et al., 2009; El-Chaar et al., 1996; Samulak et al., 1996; Toscani et al., 2000).  59 
The present study targets a large paediatric population suffering from different chronic conditions.  60 
The palatability of paediatric medicines is one of the most important formulation factors with 61 
potential to influence adherence to therapeutic regimens and outcomes (Salunke et al., 2011). It has 62 
been demonstrated that making medications more pleasing to the child can have a positive effect on 63 
compliance (Winnick et al., 2005). Refusal of a formulation was defined in the present study as, 64 
‘complete omission of a dose by intent on at least one occasion, including spitting the dose back out, 65 
and/or closing the mouth’ and medicine manipulation was defined as ‘a medicine physically adapted 66 
to facilitate medicines administration or for the purpose of giving a specific dose.’ 67 
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The importance and incentive to study the palatability of paediatric formulations was discussed in 68 
the reflection paper (EMEA, 2006) and endorsed in the latest European Paediatric guideline on 69 
pharmaceutical development of formulations for paediatric use (EMA, 2013).  70 
The aims of the present study were (i) to identify the prevalence and nature of oral formulation-71 
related barriers to medicines administration in children suffering from long-term conditions in a 72 
domiciliary environment; (ii) to identify the prevalence of children refusing formulations and also 73 
determine which formulation factors influenced oral medicines refusal and (iii) to evaluate the 74 
prevalence and nature of oral medicines manipulation by parents, carers and children in the 75 
domiciliary environment. 76 
2 Materials and Methods 77 
2.1 Data collection tool 78 
Understanding formulation acceptability in a domicilliary environment requries the use of 79 
alternative means of data collection compared to in-patient studies. A semi-structured interview was 80 
selected for this study to obtain the appropriate balance in data collection and subsequent analysis 81 
(Malim and Birch, 1996). During a semi-structured interview, the interviewer is able to show 82 
empathy and alter phrasing of questions in order to elicit detailed and considered responses from 83 
participants; these benefits have been previously shown to provide more detailed outputs (Gillham, 84 
2000) and an increased response rate (Chambers, 2000) compared to paper-based questionnaires. 85 
A multidisciplinary research team (Professor in Clinical Pharmacy, paediatric consultant and 86 
pharmacist) generated an outline of key problems with administering oral formulations to children; 87 
these issues were refined via four focus groups with healthcare professionals at the University 88 
Hospital Coventry and Warwickshire (UHCW) and Birmingham Children’s Hospital (BCH). The data 89 
collected, in addition to self-report methodologies referenced in published studies (Medical 90 
Adherence Measure - MAM (Ingerski et al., 2009; Zelikovsky et al., 2008), Treatment Interview 91 
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Protocol - TIP (Marhefka et al., 2004), Pediatric AIDS Clinical Trials Group PACTG questionnaire 92 
(NIAID) and Morisky Scales (Morisky et al., 2008; Morisky et al., 1986) were used to inform the 93 
design of the self-report semi-structured interview tool. The Young Persons Advisory Group (YPAG) 94 
at Birmingham Children’s Hospital (n=12 members) reviewed the tool to ensure that it was age 95 
appropriate.  96 
The 13-item self-report tool (Supplementary File 1) used in the semi-structured interviews was 97 
designed to collect data exploring medicines adherence including medicines refusal (see Q5 in 98 
Supplementary File 1), medicines manipulation (see Q3a in Supplementary File 1) and barriers to 99 
medicines administration (see Q3b in Supplementary File 1) in parents, carers and children 100 
themselves. Open questions were used to elicit reasons for medicines refusal to avoid bias. 101 
A semi-structured interview was conducted by a single researcher (post-graduate pharmacist (RV) - 102 
not previously known to the patients) to minimise variation in approach and the responses were 103 
entered manually onto a structured data record during each interview. The interviews (maximum 104 
duration of 45 minutes) were conducted in a private area at the paediatric outpatients department 105 
at UHCW at times scheduled to coincide with routine clinical appointments. Ethical approval was 106 
granted by the South Birmingham REC and informed consent was obtained for all participants. 107 
Participants were invited to provide demographic information in order to generate an Index of 108 
Multiple Deprivation 2010 (IMD 2010) score.  109 
 110 
2.2 Qualitative Analysis 111 
Themes were identified using a frame-work analysis approach to form a coding spine. Thematic 112 
content analysis (Pope et al., 2000) was used to identify and group common themes,relating to 113 
medicines administration. Qualitative data was analysed using NVivo 8 software (QSR International).  114 
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2.3 Statistical Analysis 115 
Statistical analysis was conducted using generalised estimating equations to explore the relationship 116 
between independent variables (e.g. child age, IMD score, formulation type) and dependent 117 
variables with binary outcomes (Refusal or Manipulation). 118 
Patient, participant and data on formulations were converted into categorical variables (see Tables 2 119 
& 3).  120 
Data analysis was performed on an individual medicine level facilitating comparisons between 121 
medicine specific variables (e.g. different medicine groups and formulations), which are not possible 122 
at a patient level. In order to account possible non-independence of data owing to any response 123 
correlation to medicines taken by an individual, univariable generalised estimating equations were 124 
used. The univariable analysis did not control for potential relationships between independent 125 
variables therefore multivariable analysis was also conducted using the combination of independent 126 
variables found to be significant (p<0.05) for the dependent variables in the univariable model 127 
(medicines refusal, medicines manipulations). This generated Odds Ratios, 95% confidence intervals 128 
and associated p values. The data was analysed using  SPSS version 20 software (IBM). 129 
 130 
2.4 Study Setting and Study Participants 131 
A pragmatic approach was employed to identify and recruit participants resulting in a total of 1559 132 
study invitation letters being posted to patients (via their parent/carer) due to attend follow-up 133 
paediatric clinics (1448/1559) or handed out on the paediatric wards (111/1559) at UHCW. Study 134 
interviews were conducted with parents or carers (if legal guardians) of children or young people, or 135 
with young people directly. The opportunity to assent and participate alone was given to 12-16 year 136 
olds providing parent or carer consent was also obtained.  Young people over 16 years of age were 137 
permitted to consent alone and encouraged to discuss the study with a parent or legal guardian 138 
before providing consent. It was necessary to include young people (those over 12 years of age), 139 
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where appropriate as this sub-population reported increased personal management of their 140 
medicines administration. Parents or carers views were more useful for younger children where they 141 
may not have the cognitive capability to participate alone. 142 
Age-appropriate study information was provided to potential participants at least 24 hours before 143 
asking for participation in the study. 144 
A total of 191 general and speciality outpatient clinics were targeted covering a wide range of 145 
chronic conditions (e.g. epilepsy, cystic fibrosis, neoplasms, cardiac disorders, endocrine disorders, 146 
tuberculosis, HIV, renal diseases, rheumatological diseases and survivors of neonatal intensive care). 147 
It should be noted that not all patients in clinics were prescribed medicines, therefore not all 148 
patients were eligible for study inclusion. There was a scheduled approach to accessing patients at 149 
these clinics on a rotating basis to ensure wide coverage of the target patient population. UHCW is a 150 
teaching hospital with three age-banded paediatric wards. All have a wide range of paediatric 151 
patients without specialism. Inpatients from all three paediatric wards at UHCW were included at 152 
the recruitment phase to minimise the risk of missing eligible patients who were hospitalised during 153 
the study period. The recruitment phase lasted 15 months from November 2010 to February 2012.  154 
2.4.1 Inclusion criteria 155 
The study included children (aged 0- <18 years) with chronic conditions and their parents or carers. 156 
Age bandings were based on pre-school; school-age and adolescents to match cognitive function. 157 
Patients were eligible for inclusion if they had been taking prescribed medication for a chronic 158 
condition for at least one month prior to their outpatient appointment.  159 
3 Results 160 
A total of 280 participants consented to the study (Figure 1). Interviews were completed with 221 161 
parents/carers and 57 young people (in the presence of a parent/carer (n=42), in the absence of a 162 
parent/carer (n=15)). In total, (91%) 252/278 of the children included were prescribed at least one 163 
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oral formulation.  The remaining 26 patients were not prescribed any oral formulations, only non-164 
oral formulations. The data from these patients was analysed separately and is not included in the 165 
subsequent analyses. 166 
 167 
3.1 Participant demographics and medicines 168 
The 252 children receiving oral formulations were categorised into three age groups: 0-4 years 169 
(n=92), 5-11 years (n=93) and 12-18 years (n=67), see Table 1 for the frequency of oral formulation 170 
types prescribed. 171 
Table 1: The frequency of oral formulation types prescribed across child age ranges 0-4y, 4-12y and 172 
12-18y 173 






Total in 252 
children 
Liquids  130 86 36 252 
Tablets or capsules  20 61 96 177 
Other (granules, powders, soluble tablets and melts) 49 47 17 113 
Totals  199 194 149 542 
n represents the number of children in each age range (0-4, 5-11 and 12-18 years) 174 
In total, 542 oral formulations were prescribed across the cohort (with the number of oral 175 
formulations prescribed to each patient ranging from 1 to 8). 176 
Of these oral formulations, 8% (41/542) were identified as ‘Specials’ (i.e. unlicensed formulations 177 
prepared under the terms of a Marketing Authorisation, granted by the Medicines and Healthcare 178 
products Regulatory Agency) (MHRA). 179 
 180 
3.2 Medicines refusal 181 
In total, 232/252 of participants answered the question (Q5 see Supplementary File 1) about the 182 
refusal of formulations, resulting in data on 436/542 of formulations. Of these, 8% (44/542) of 183 
formulations were administered via nasogastric or percutaneous endoscopic gastrostomy tubes and 184 
medicine refusal was not permitted, therefore data is unavailable on these medications for 10 185 
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patients. The medicines refusal question was not delivered to a further 10 participants owing to time 186 
constraints. Almost one third (71/232) of respondents reported medicines refusal on at least one 187 
occasion; multivariable statistical analysis was conducted on this data set. The results are reported in 188 
Table 2.  189 
Table 2: Multivariable analysis results: Reports of medicines refusal on at least one occasion 190 
  Odds Ratio (95% CI) p Value 
Age of child at Interview   0.016* 
0-4 years 1  
5-11 years 0.42 (0.19 - 0.89) 0.024* 
12-18 years 1.31 (0.54 - 3.20) 0.554 
IMD 2010 score   0.002* 
<11.5 1   
11.5-19.8 1.32 (0.49-3.51) 0.584 
19.9-31.9 3.19 (1.37-7.43) 0.007* 
32+ 4.75 (2.02-11.18) <0.001* 
Formulation type   0.336 
Liquid 1   
Capsules and Tablets 0.59 (0.27-1.30) 0.193 
Other (granules, powders, soluble tablets 
and melts) 0.64 (0.30-1.38) 0.254 
Problem with taste   <0.001* 
No 1   
Yes 3.82 (2.11-6.92) <0.001* 
Problem with texture   0.017* 
No 1   
Yes 3.38 (1.24-9.22) 0.017* 
Problem with volume or quantity    <0.001* 
No 1   
Yes 12.79 (4.41-37.12) <0.001* 
Problem with smell   0.776 
No 1  
Yes 1.24 (0.28-5.46) 0.776 
p values marked with * identify statistically significant results (p<0.05).  191 
The age of child at interview was found to be a significant predictor of refusal, with children aged 192 
between 5-11 the least likely to have refused medicines (OR=0.42, relative to the 0-4 year group; 193 
95% CI: 0.19-0.89; p=0.024). However, no significant difference was detected between the likelihood 194 
of medicines refusal in the 12-18 years group, relative to the 0-4 years group (OR=1.31; 95% CI: 0.54-195 
3.20; p=0.554). The likelihood of medicines refusal was found to increase significantly (p=0.002) 196 
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across the IMD score groups, peaking at an odds ratio of 4.75 (95% CI: 2.02-11.18; p<0.001) in the 197 
most deprived patient group (IMD=32+) relative to the least deprived (IMD<11.5). 198 
A range of medicines related factors were also found to be associated with refusal in children. 199 
Patients who had problems with the volume or quantity of medication were considerably more likely 200 
to have a history of medicines refusal (OR=12.79; 95% CI: 4.41-37.12; p<0.001), with issues with 201 
either taste (OR=3.82; 95% CI: 2.11-6.92; p<0.001) or texture (OR=3.38; 95% CI: 1.24-9.22; p=0.017) 202 
also being significant predictors of refusal. However, after accounting for these factors, there was no 203 
significant evidence that either the smell (p=0.776), or the type of formulation (p=0.336), had any 204 
impact on refusal rates. 205 
3.3 Medicines manipulation 206 
Almost one third (74/252) of respondents reported manipulating formulations.  207 
In total, 19% (94/499) of formulations were manipulated. Of these, the majority (93%, 87/94) were 208 
reported to be manipulated ‘always’ (i.e. prior to every dose administration). 209 
 210 
Of the medicine manipulations reported, 26% (24/94) were performed for the purpose of 211 
administering a specific dose (e.g. one quarter of a tablet), whilst the majority of medicine 212 
manipulations, 79% (74/94) were performed to facilitate medicines administration (e.g. mixed into 213 
foodstuffs). Omeprazole soluble tablets, macrogol 3350 oral powder, co-trimoxazole tablets and 214 
mercaptopurine tablets were most often manipulated (by at least 40% of users). For over three 215 
quarters (78% 7/9) of children prescribed omeprazole soluble tablets, medicines manipulation was 216 
reported.  217 
The age of the child at the interview was found to be a significant predictor of the reporting of 218 
medicines manipulation (p=0.005). Reports became progressively less likely with increasing age, with 219 
Odds Ratios of 0.29 (95% CI: 0.13-0.67; p=0.004) in the 5-11 year age group, and 0.18 (95% CI: 0.06-220 
0.59; p=0.005) in the 12-18 year age group, relative to patients in the 0-4 year group. 221 
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The type of formulation was also associated significantly with reporting of medicines manipulation 222 
(p<0.001), with tablets and capsules (OR: 9.66; 95% CI: 3.48-26.87; p<0.001) and other formulations 223 
(granules, powders, soluble tablets and melts) (OR: 23.97; 95% CI: 9.14-62.84; p<0.001) both more 224 
likely to be manipulated than liquids. Manipulation was also found to be significantly more likely to 225 
be reported where patients had problems with either the size (OR: 4.52; 95% CI: 1.37-14.90; 226 
p=0.013) or the texture (OR: 3.15; 95% CI: 1.39-7.14; p=0.006) of the medicines. In cases where the 227 
child had partial responsibility for the administration of a medicine, significantly lower rates of 228 
manipulation were reported, relative to where the parent or guardian was solely responsible (OR: 229 
0.28; 95% CI: 0.10-0.81; p=0.019). A similar effect was observed where the child was totally 230 
responsible for medicines administration, although this was not statistically significant (OR: 0.22; 231 
95% CI: 0.02-1.94; p=0.171). The results are reported in Table 3. 232 
Table 3:  Multivariable analysis results: Reports of medicines manipulation 233 
  Odds Ratio (95% CI) P Value 
Age of child at Interview   0.005* 
0-4 years 1  
5-11 years 0.29 (0.13-0.67) 0.004* 
12-18 years 0.18 (0.06-0.59) 0.005* 
Is English first language of participant   0.085 
Yes 1  
No 0.26 (0.06-1.20) 0.085 
Formulation type   <0.001* 
Liquid 1  
Tablets and Capsules 9.66 (3.48-26.87) <0.001* 
Other (granules, powders, soluble tablets 
and melts) 23.97 (9.14-62.84) <0.001* 
Problem with size of dosage form or 
aversion to/difficulty swallowing dosage 
form    0.013* 
No 1  
Yes 4.52 (1.37-14.90) 0.013* 
Problem with texture   0.006* 
No 1  
Yes 3.15 (1.39-7.14) 0.006* 
Problem related to other formulation and 
administration problems   0.206 
No 1  
Yes 1.89 (0.70-5.08) 0.206 
12 
 
Who is responsible for medicines 
administration   0.049* 
Parent/Guardian 1  
Child plus Parent/Guardian 0.28 (0.10-0.81) 0.019* 
Child 0.22 (0.02-1.94) 0.171 
Problem with volume or quantity   0.157 
No 1   
Yes 2.17 (0.74-6.35) 0.157 
Frequency of dosing   0.404 
1x daily 1   
2x daily 0.70 (0.34-1.45) 0.345 
≥3x daily 0.20 (0.03-1.46) 0.113 
<1x daily (not including medicines 
prescribed on a ‘when required’ basis)  0.76 (0.23-2.46) 0.647 
p values marked with * identify statistically significant results (p<0.05). 234 
 235 
3.4 Barriers to oral medicines administration 236 
3.4.1 Taste 237 
Taste was the most commonly reported barrier to medicines administration affecting 35% (188/542) 238 
of all prescribed oral formulations, and associated with 64% (54/85) of formulations that were 239 
refused. 240 
Formulations with the highest incidence of taste issues were ranitidine liquid (82%; 9/11 children), 241 
prednisolone soluble tablets (81%; 13/16 children) and trimethoprim liquid (75%; 6/8 children) of 242 
total users. However, taste issues were reported for at least 50% of children prescribed other 243 
common drugs (lactulose liquid, macrogol 3350 oral powder sachets, co-trimoxazole tablets, sodium 244 
valproate liquid, levetiracetam liquid, penicillin liquid, ibuprofen liquid and prednisolone tablets). 245 
See Figure 2 for reported taste problems. 246 
3.4.2 Texture 247 
Texture was reported to affect 8% (42/542) of all prescribed oral formulations, and was a significant 248 
predictor of medicines refusal. Co-trimoxazole liquid (38%), omeprazole soluble tablets (33%) and 249 
lactulose liquid (25%) were most commonly reported to have texture-related problems. Specific 250 
medicines identified with textural issues included: lactulose which was described as “oily” and co-251 
trimoxazole liquid described as “thick and gelatinous”  252 
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3.4.3 Volume or Quantity 253 
Of the medicines prescribed, 5% (29/542) were reported to have “too large” a volume or “too many” 254 
solid dosage units to be administered at one dosing interval. Volume or quantity were reported as 255 
barriers to administration for 63% (5/8) of children prescribed pancrealipase capsules, 40% (12/30) 256 
of children prescribed macrogol 3350 oral powders and 19% (3/16) of children prescribed 257 
prednisolone soluble tablets.  258 
3.4.4 Size and aversion to or difficulty with swallowing 259 
Problems related to i) the size of a solid dosage form or ii) aversion to or difficulty swallowing a solid 260 
dosage form was associated with 5% (28/542) of the total medicines prescribed (16% if only solid 261 
dosage forms considered). 262 
For 16% (28/177) of solid dosage forms prescribed to patients, problems experienced either with the 263 
size of a solid dosage form or where children were averse to swallowing a solid dosage form were 264 
reported. Problems specifically related to the sizes of particular solid dosage forms were reported 265 
for 68% (19/28) of these medicines, and aversion to, or difficulty swallowing solid dosage forms was 266 
reported for the remaining 32% (9/28) of medicines. It should be noted that these patients were not 267 
physically unable to swallow (i.e. not patients fitted with an NG or PEG tube). The majority (7/8= 268 
88%) of patients prescribed co-trimoxazole tablets reported a problem with their large size or 269 
difficulties swallowing them. These children were aged from 4 to 15 years. Although specific data on 270 
brand of formulation was not collected from parents, the size of co-trimoxazole tablets (480mg) was 271 
measured to be an average of 11mm (based on the average diameter of two different 272 
manufacturers).This could be expected based on the large amount of active ingredient within the 273 
formulation. In contrast, there were no problems reported with the size of levothyroxine tablets, 274 
owing to their significantly lower dose (micrograms) and therefore a comparatively smaller tablet. 275 
3.4.5 Colour/appearance and smell  276 
An unfavourable colour (descriptions provided included “alarming”, off-putting, and colourless) was 277 
associated with 2% (11/542) of medicines prescribed. Two of eighteen  children prescribed sodium 278 
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valproate liquid highlighted its “alarming colour” .. Similarly, one of nine patients prescribed 279 
paracetamol liquid described its unappealing colour. 280 
In addition, 2% (11/542) of medicines prescribed were identified as having “off-putting” smells. For 281 
25% (2/8) of children prescribed trimethoprim liquid, an unfavourable smell was reported. 282 
4 Discussion 283 
This study has indicated that formulations prescribed to children with chronic conditions are not 284 
meeting the needs of a significant number of patients based on self-report. Medicines refusal was 285 
associated significantly with barriers to oral medicines administration: taste, texture, 286 
quantity/volume (see Table 2). Palatability needs to be considered carefully by pharmaceutical 287 
companies when designing new formulations and also by prescribers in order to optimise effective 288 
prescribing, maximising adherence, therapeutic effects and reducing wastage with cost savings. 289 
Other statistically significant factors associated with medicines refusal were child age at interview 290 
and IMD 2010 score. Recent EMA guidance (EMA, 2013) states that age-appropriateness of 291 
formulations needs to be prominent in pharmaceutical development and also when designing 292 
prescribing protocols for prescribers. Further research is required to investigate the relationship 293 
between socio-demographic factors and medicines refusal. 294 
The formulations highlighted to be problematic are also often prescribed to treat patients with acute 295 
conditions, e.g. soluble prednisolone tablets. Evaluation of the study data can inform changes in 296 
prescribing practice, e.g. prescribing prednisolone tablets in preference to soluble prednisolone 297 
tablets for children; even though intuitively soluble tablets are considered to be age-appropriate for 298 
paediatric populations. This change has been implemented at UHCW and it is estimated that this will 299 




This study identified that almost one third (29%) of participants reported manipulating medicines. 302 
Studies conducted in specific patient groups (HIV (Byrne et al., 2002; Goode et al., 2003; Wrubel et 303 
al., 2005) and oncology (Christiansen et al., 2008)), reported similar findings. Several examples of 304 
medicines manipulation that could affect drug bioavailability and thus therapeutic response were 305 
identified and their potential physicochemical effects are reported in Table 4 below. 306 
 307 
Table 4: Potential physicochemical effects of medicines manipulation   308 
Manipulation techniques reported within this study Potential physicochemical effects of manipulation techniques 
(general examples; not tested with specific formulations 
reported within this study) 
 Splitting tablets (co-trimoxazole tablets) or sachets manually 
(Gaviscon infant oral powders) 
Inaccurate segmentation resulting in administration of inaccurate 
dose (underdose versus overdose) 
Mixing non-soluble tablets with liquids (azathioprine tablets) Non-uniform dosing, aggregation and sedimentation of insoluble 
drug particles 
Crushing tablets (hydrocortisone tablets) Thermal degradation 
Mixing with foodstuffs (sodium valproate liquid) Fruit juices (altering pH), drug binding to dairy proteins, formation 
of insoluble complexes 
Limited evidence is available on the effects of mixing drugs with various foodstuffs. Prolonging the 309 
contact time of a drug with a foodstuff is likely to increase the binding capability and therefore may 310 
risk reducing drug bioavailability, thus affect therapeutic response. Additionally, if a drug-foodstuff 311 
mixture is not consumed in its entirety, the desired dose will not be administered.  312 
To minimise unnecessary medicines manipulation it is essential that prescribers consider age-313 
appropriateness, type of formulation (in relation to ease of administration), swallowing problems 314 
and patient capability to swallow tablets according to size and also acceptance of different textures. 315 
These factors were associated significantly with manipulation of medicines (see Table 3). The lower 316 
reported refusal of solid dosage forms compared to liquids (see Table 2) may be associated with the 317 
adoption of ad hoc manipulation techniques, and supporting this, medicines manipulation was 318 
significantly associated with administering solid dosage forms (see Table 3). 319 
Future formulation work needs to be implemented to develop age-appropriate formulations that are 320 
accepted by children and are also available in appropriate unit doses, ideally pre-measured, covering 321 
child dosing ranges and also small enough to taper doses accurately. Dosage form technologies such 322 
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as mini-tablets (Spomer et al., 2012; Thomson et al., 2009) may help to reduce the perceived need to 323 
manipulate some medicines. However, it should be acknowledged that for some medicines, it may 324 
be more feasible for practical and economical reasons to use safe and effective manipulation 325 
techniques. Owing to the limited data available and also poor understanding of healthcare 326 
professionals regarding the safety and efficacy of medicines manipulation (Akram and Mullen, 2012; 327 
Venables et al., 2012) it is vital that laboratory work is conducted to provide a robust scientific 328 
evidence base to support safe and effective medicines manipulation.  329 
It would be useful for future studies to investigate if education to help children to learn to swallow 330 
tablets could improve medicines adherence. Studies investigating infant acceptance of different 331 
tastes and textures of foodstuffs (Harris, 2008; Northstone et al., 2001) agree that encouraging 332 
children to accept solid dosage forms from a younger age may be beneficial. This could minimise 333 
child aversion to some formulations and also reduce unnecessary modification to medication.  334 
The present study is pragmatic, of multi-perspective design and has a large paediatric sample size. It 335 
has expanded the pre-existing, narrowly focussed literature and identified the prevalence and 336 
nature of barriers to oral medicines administration in children with chronic conditions. 337 
Complementing the findings of this study, two other studies (Richey et al., 2011; Skwierczynski and 338 
Conroy, 2008) identified the nature and frequency of manipulations to formulations administered to 339 
children on paediatric wards. Identification of the difficulties experienced by families when 340 
administering formulations to children is essential for directing future formulation development 341 
work. User involvement has played a fundamental role throughout the present study. 342 
A limitation within the present study is the reporting of generic formulations as opposed to specific 343 
products (e.g. brands and manufacturers). This results from the nature of this pragmatic study which 344 
relies upon parent/carer/patient reports. Nonetheless, this is the first study to explore barriers to 345 
oral medicines administration in children with a wide range of chronic conditions. Further research is 346 
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required to identify whether similarly, problems are encountered with non-oral medicines and in 347 
paediatric populations outside of the UK.  348 
A limitation of using a self-report tool is the risk of inaccurate reporting (Butz, 2006). In this study, 349 
one mother reported that medication had not been omitted, however the adolescent in her care 350 
provided an opposing report. This finding reinforces the need for future studies to investigate parent 351 
and teenager reports independently.  In the present study, there was insufficient time and resources 352 
for parents and young people to be interviewed independently and the study was designed to be 353 
pragmatic, thus reflect a family environment. A study by Buchanan and co-workers (2012) found 354 
significant similarity between independent reports of ‘taste/cannot get it down’ (p<0.001), 355 
forgetting (p<0.001), and also refusing doses (p=0.01) amongst young people with HIV and their 356 
carers. These findings suggest that reporting of such outcomes is fairly consistent between carers 357 
and young people, however this is only one study, conducted in children with HIV. 358 
The statistical results may have been subject to confounding by other factors that were not 359 
considered in the analysis and should be interpreted in light of this. However, since a range of 360 
variables were considered in the analysis and a multivariable statistical approach was used, 361 
confounding factors have been accounted for as far as was possible. 362 
5 Conclusions 363 
Almost one third (31%) of respondents reported medicines refusal on at least one occasion and 29% 364 
reported manipulating formulations. Study findings indicate that oral formulations prescribed to 365 
children are not suitable for a significant number of patients. Adherence and hence expected 366 
therapeutic response will be potentially affected. Medicines manipulation can be a serious burden 367 
for parents or carers, particularly when children are prescribed several formulations. Age-368 
appropriate formulations should be developed to provide both suitable dose units and acceptable 369 
taste. Further laboratory work is required to provide robust scientific evidence to support medicines 370 
18 
 
manipulation techniques suitable for use in the domiciliary environment with attention to patient 371 
safety and drug efficacy. In addition, prescribers and pharmacists need to be vigilant when making 372 
prescribing and supply decisions respectively, to ensure that they are choosing the most appropriate 373 
formulation for an individual patient. 374 
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